<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Suppes, Trisha</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Lurasidone Effective in Major Depressive Disorder With Mixed Features</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-11 13:08:33</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">The first-ever placebo-controlled trial in major depressive disorder with mixed features demonstrated that lurasidone, an atypical antipsychotic agent, was efficacious in reducing depressive symptoms in these patients and was also well tolerated when compared with placebo.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>